Compare Intercontinental Exchange Inc. Common Stock (ICE) vs Natera Inc. Common Stock (NTRA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Intercontinental Exchange Inc. Common Stock vs Natera Inc. Common Stock — how do they compare? Intercontinental Exchange Inc. Common Stock trades at $156.7 (market cap $87.81B), while Natera Inc. Common Stock trades at $394.6 (market cap $57.03B). The key difference: Intercontinental Exchange Inc. Common Stock is the larger of the two by market cap, and Intercontinental Exchange Inc. Common Stock pays a 1.33% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals.
| ICE | NTRA | |
|---|---|---|
Market Cap | $87.81B | $57.03B |
Volume | 3,190,982 | 1,131,157 |
Sector | Financials | Health |
52-Week High | $175.10 | $425.64 |
52-Week Low | $122.91 | $179.42 |
Enterprise Value | $105.72B | $56.18B |
Dividend Yield | 1.33% | — |
Typical Hold Time | — | 0 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Intercontinental Exchange (ICE) trades at $156.42, down 0.64% on the day, with strong technical momentum showing bullish moving averages and key support at $155. The company demonstrates robust fundamentals with Q2 2026 EPS beating expectations at $1.90 versus $1.84, maintaining a three-quarter beat streak. Revenue growth accelerated to $13.4 billion in 2026 with net profit margin expanding to 30.07%, supported by record trading volumes in key markets.
ICE presents a compelling investment case with 89% analyst buy ratings and a $183.89 consensus price target implying 17.6% upside. The exchange operator's diversified platform and recurring revenue model provide stability, though investors should monitor competitive pressures and market volatility impacts. Strong cash flow generation and institutional support reinforce the bullish outlook despite near-term technical overbought conditions.
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Intercontinental Exchange Inc. Common Stock
Intercontinental Exchange provides technology and data services for financial institutions, corporations, and governments. Its businesses include exchanges and clearing, fixed-income data and analytics, and mortgage technology.
Read more on ICE →About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →
